<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03613935</url>
  </required_header>
  <id_info>
    <org_study_id>17.19.BIO</org_study_id>
    <nct_id>NCT03613935</nct_id>
  </id_info>
  <brief_title>Effect of Changes in Glucose Intake and Sweet Perception on Post Prandial Glycaemia</brief_title>
  <official_title>Effect of Changes in Glucose Intake and Sweet Perception on Post Prandial Glycaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sugar-sweetened beverages are the main source of added sugars in most Westernized countries,
      and for this reason constitute a primary target for sugar reduction by many companies,
      including Nestlé. Instead of using high-intensity sweeteners which are non-caloric in nature,
      an alternative would be to reduce sugars without altering sweetness.

      In this protocol, the general goal is to investigate the relative contribution of sweet taste
      perception and sugar intake on post-prandial glucose response. 4 different nutritional
      products will be tested by 16 healthy subjects in a crossover design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After enrollment, participants will be asked to come to the investigational site 6 times for:

        -  two sensory tests dedicated to assess the sensory capacity of the participants from the
           same sensory test repeated twice, for better consistency.

        -  4 testing visits for a 3-h blood kinetics after each product intake. These visits will
           be scheduled on different days separated by a washout period of at least one week.
           Outcomes will be glycemia and insulinemia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2018</start_date>
  <completion_date type="Actual">April 20, 2018</completion_date>
  <primary_completion_date type="Actual">April 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a monocentric, controlled, randomized, open, complete crossover study design</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incremental Area under the Curve (iAUC) of plasma glucose</measure>
    <time_frame>0 to 3 hours post product intake</time_frame>
    <description>Area under the curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incremental Area under the Curve (iAUC) of plasma insulin</measure>
    <time_frame>0 to 3 hours post product intake</time_frame>
    <description>Area under the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of plasma glucose</measure>
    <time_frame>between 0 and 3 hours post product intake</time_frame>
    <description>Maximal concentration of plasma glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of plasma insulin</measure>
    <time_frame>between 0 and 3 hours post product intake</time_frame>
    <description>Maximal concentration of plasma insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of plasma glucose</measure>
    <time_frame>between 0 and 3 hours post product intake</time_frame>
    <description>Time (min) for maximal concentration of plasma glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of plasma insulin</measure>
    <time_frame>between 0 and 3 hours post product intake</time_frame>
    <description>Time (min) for maximal concentration of plasma insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory tasting capacity</measure>
    <time_frame>immediately after product intake</time_frame>
    <description>Assessment of the sweetness of two beverages versus control through a questionnaire</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Product 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal glucose, isosweet, homogeneous: 43 g glucose beverage, with a 43 g glucose equivalent sweetness homogenously delivered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low glucose, isosweet, heterogeneous: 30 g glucose beverage with 43 g glucose equivalent sweetness heterogeneously delivered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low glucose, less sweet, homogeneous: 30 g glucose beverage with a 30 g glucose equivalent sweetness homogenously delivered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low glucose+sucralose, isosweet, homogeneous: 30 g glucose + 18 mg sucralose beverage with a 43 g glucose equivalent sweetness homogenously delivered</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product 1</intervention_name>
    <description>Comparison with products 2, 3, and 4</description>
    <arm_group_label>Product 2</arm_group_label>
    <arm_group_label>Product 3</arm_group_label>
    <arm_group_label>Product 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product 2</intervention_name>
    <description>Comparison with products 1, 3, and 4</description>
    <arm_group_label>Product 1</arm_group_label>
    <arm_group_label>Product 3</arm_group_label>
    <arm_group_label>Product 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product 3</intervention_name>
    <description>Comparison with products 1, 2, and 4</description>
    <arm_group_label>Product 1</arm_group_label>
    <arm_group_label>Product 2</arm_group_label>
    <arm_group_label>Product 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product 4</intervention_name>
    <description>Comparison with products 1, 2, and 3</description>
    <arm_group_label>Product 1</arm_group_label>
    <arm_group_label>Product 2</arm_group_label>
    <arm_group_label>Product 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI between 18.5 and 29.9 kg/m2

          -  Fasting capillary blood glucose level ≤ 7 mmol/L

          -  Able to understand and sign an informed consent form

        Exclusion Criteria:

          -  Pregnancy on anamnesis

          -  Lactating mothers

          -  Individuals undergoing either dietary or exercise mediated weight loss program
             prescribed by a health care professional

          -  Medically-treated diabetes mellitus or use of anti-hyperglycemic drugs or insulin

          -  Family history of type 2 diabetes (parents)

          -  Any other metabolic disease possibly impacting the postprandial glucose and insulin
             response (to the opinion of the medical doctor)

          -  Known ageusia or other tasting trouble

          -  Chronic intake of medications known to affect glucose tolerance to the opinion of the
             investigator (steroids, protease inhibitors, antidepressants, anxiolytic, or
             antipsychotics)

          -  Presence of disease or intake of drug that affects digestion and absorption of
             nutrients, to the opinion of the medical doctor

          -  Major medical/surgical event requiring hospitalisation in the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurice Beaumont, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nestlé</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nestlé Research Center</name>
      <address>
        <city>Lausanne</city>
        <zip>1000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>August 2, 2018</last_update_submitted>
  <last_update_submitted_qc>August 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

